Rationale: Targeted genetic engineering using programmable nucleases such as transcription activator-like effector nucleases (TALENs) is a valuable tool for precise, site-specific genetic modification in the human genome.
C ardiovascular disease is a major cause of morbidity and mortality around the world. In recent years, exciting progress has been made in defining the pathogenesis of congenital heart disease (CHD) 1 and inherited cardiomyopathies, 2 including hypertrophic cardiomyopathy, dilated cardiomyopathy (DCM), left ventricular noncompaction, and arrhythmogenic right ventricular cardiomyopathy/dysplasia. Recent advances in genomics and molecular medicine have identified genetic mutations in plethora of genes that are implicated in the pathogenesis of inherited cardiomyopathies. Although the molecular analysis efforts have revealed important insights about the role of genetics in cardiomyopathies, the underlying molecular mechanisms remain poorly understood and the genotypephenotype relationship from the ever-growing number of disease-associated gene mutations remains to be established.
Recent advances in technologies for genome editing using site-specific nucleases, 3 such as zinc finger nucleases, transcription activator-like effector nucleases (TALENs), and the clustered regularly interspaced short palindromic repeat/ CRISPR-associated protein 9 (CRISPR/Cas9) system, offer a powerful tool for reverse genetics, genome engineering, and targeted transgene integration experiments to be performed in a precise and predictable manner. The use of engineered nucleases to make targeted, permanent changes to genes have revolutionized molecular genetics and present an alternative to the more established method of RNA interference (RNAi)-mediated knockdown using short hairpin RNA (shRNA) or short interfering RNA (siRNA). However, the RNAi-mediated post-transcriptional downregulation of gene expression without changing the genetic code does not completely shut off the gene of interest. 4 In most cases, functional RNA or protein remains and is translated albeit at lower levels. Thus, the gene function is reduced, but not eliminated. By contrast, genome editing changes the genetic code and typically causes a functional "knockout", or complete elimination of the gene function. The nucleases cut both DNA strands of the targeted locus generating a double-strand break in the chromosome, which is then repaired by the nonhomologous end joining (NHEJ) mechanism that religates the 2 free chromosome ends. However, NHEJ is error-prone, often resulting in small insertions or deletions that can disrupt, or knockout, the gene of interest.
Over the past decade, the advent of the human-induced pluripotent stem cell (iPSC) technology, and the improvements in the differentiation method of iPSCs into specific cell types, such as cardiac myocytes (iPSC-CMs), 5 endothelial cells (iPSC-ECs), 6 and smooth muscle cells (iPSC-SMCs), 7 provide an unprecedented opportunity for the generation of patient-specific in vitro models for disease modeling.
Combining genome editing and iPSC technologies can successfully create human-based cell knockout models in vitro. Such models could improve our understanding of the underlying pathological mechanisms, and potentially lead to novel therapies. 8 In this study, we describe the design, construction, and validation of a cardiomyopathy TALEN-based panel to knockout a comprehensive set of genes associated with cardiovascular diseases. We demonstrated the use of this panel and presented 2 case studies that provided novel insights into the pathogenesis of genetic cardiovascular disease. The readily available cardiomyopathy TALEN-based panel will allow researchers to fast-track projects by providing a validated panel of TALEN constructs for gene knockout genome editing. This approach could provide novel insights into gene function, disease mechanisms, and ultimately disease pathogenesis.
Methods

TALEN Construction
TALEN genomic binding sites were designed using the TAL Effector Nucleotide Targeter 2.0, 9 with the following constraints: (1) having a repeat array length of 15 repeat variable di-residue domains and (2) having a spacer length of 14 to 18 nucleotides. A preceding T base in position "0" anchored each binding site as has been shown to be optimal for naturally occurring TAL proteins. 10, 11 Each custom TALEN was generated from a library of 832 plasmids through a 
Novelty and Significance
What Is Known?
• Advances in cardiovascular genetics have uncovered many genes associated with inherited cardiomyopathies.
• The use of human-induced pluripotent stem cell-derived cardiac myocytes (iPSC-CMs) provides an unprecedented opportunity for the generation of human cell-based disease models to study genetic cardiomyopathies.
What New Information Does This Article Contribute?
• Transcription activator-like effector nucleases facilitate gene knockout with high efficiency, precision, and accuracy.
• Successful creation of human-based knockout cell models in vitro by combining genome editing and iPSC-CM technologies.
• Transcription activator-like effector nuclease-mediated allele-specific knockout ameliorate dilated cardiomyopathy-associated phenotypes in iPSC-CMs in vitro.
• Modeling Holt-Oram syndrome in iPSC-CMs in vitro uncovered novel genes and pathways regulated by TBX5.
The advent of human iPSC technology and an increasingly refined capacity to differentiate iPSCs into disease-relevant cell types, such as iPSC-CMs, provides an unprecedented opportunity for the generation of human cell-based disease models to study genetic cardiomyopathies. Genome editing can be used to change the DNA in iPSCs to aid the understanding of the biology of cardiomyopathyassociated genes and how they work. We can now make changes (or "edits") to the DNA in specific location in the genome using an "engineered nuclease", an enzyme that can be tailored to cut the genome in a specific place. Here we harnessed this technology to generate iPSC-based knockout models of genetic cardiomyopathies to study the underlying pathogenic phenotypes and mechanisms, as well as to genetically correct the disease in vitro. Implementation of this unique and clinically relevant model system presents a significant advantage in cardiovascular research as it can circumvent complications in translating data from models across different species and biological characteristics. Ultimately, a better understanding of molecular mechanism(s) of genetic cardiomyopathies could provide opportunities for diagnosis and prognosis as well as enable the development of personalized therapeutic interventions.
5-piece subcloning ligation: 3 sequence-specific tetramer-recognition pieces, 1 trimer-recognition piece, and an expression vector backbone (pTAL) as previously described. 12 Briefly, the tetramer or trimer TAL repeats were digested out of library plasmids with the restriction enzyme BsmBI (NEB), gel purified, and subcloned into the pTAL vectors. The forward and reverse TALENs were subcloned into the pTAL_GFP and pTAL_RFP backbones, respectively. The sequences of all constructs used in this study are provided in the Online Data Supplement. The TALEN plasmids will be available from Addgene. The cell lines are available on request from the Stanford CVI iPSC Biobank (http://med.stanford.edu/scvibiobank.html).
Culture and Cardiac Differentiation of iPSCs
The human iPSC lines (Stanford Cardiovascular Institute [SCVI-15, SCVI-114, and SCVI-19) were obtained from the Stanford CVI iPSC Biobank. The iPSCs were maintained under feeder-free conditions in defined E8 media (Life Technologies) on tissue culture plates coated with hESC-qualified Matrigel (BD Biosciences) in 5% CO 2 /5% O 2 /90% N 2 environment at 37°C. Human iPSCs were differentiated toward CMs using a small molecule-mediated directed differentiation protocol. 13 Briefly, cardiac differentiation was initiated by the treatment with recombinant BMP4 and Activin A (days 0-3), followed by the treatment with 5 μmol/L IWR-1 for 72 hours (days 4-6).
TALEN Transfection
Human iPSCs were enzymatically dissociated with Accutase (Sigma) and plated on Matrigel-coated dishes at 1:3 ratio in E8 supplemented with 10 µmol/L Y-27632 (Selleck Chemicals). Twenty-four to forty hours later, human iPSCs were dissociated with Accutase into single cells. Approximately 2×10 6 cells were transfected with a pair of TALENs (1.0 μg of each TALEN) by nucleofection using the Amaxa 4D Nucleofector system (Lonza) with the P3 Primary Cell Nucleofector Kit and program CM-150 per manufacturer's instructions (Lonza). Following nucleofection, iPSCs were resuspended in 1 mL of prewarmed E8 supplemented with 5 μmol\L Thiazovivin and then plated in 6-well plates precoated with Matrigel and allowed to recover for 48 hours.
SMRT Sequencing
Genome-editing outcomes at the endogenous loci were quantified using single-molecule real-time (SMRT) DNA sequencing as previously described.
14 Genomic DNA was extracted from TALENtransfected iPSCs at 72 hours post nucleofection without enrichment for transfected cells, and used as a template for PCR amplification using primer pairs designed to amplify a ≈500 bp fragment surrounding the TALEN targeted loci. The PCR amplicons were purified using the nucleotide removal kit (Qiagen), and the sequencing libraries were constructed using the DNA Template Prep Kit 1.0 (Pacific Biosciences). SMRTbell libraries contained amplicons that were pooled together with different barcodes appended to allow multiplex analysis. Purified, closed circular SMRTbell libraries were annealed with a sequencing primer complementary to a portion of the singlestranded region of the hairpin. For all SMRTbell libraries, annealing was performed at a final template concentration between 30 and 60 nmol/L, with a 20-fold molar excess of sequencing primer. All annealing reactions were carried out at 80°C for 2 minutes, with a slow cool to 25°C at a rate of 0.1°C/s. Annealed templates were stored at −20°C until polymerase binding. DNA polymerase enzymes were stably bound to the primed sites of the annealed SMRTbell templates using the DNA Polymerase Binding Kit 2.0 (Pacific Biosciences). SMRTbell templates (3 nmol/L) were incubated with 6 nmol/L of polymerase in the presence of phospholinked nucleotides at 30°C for 2 hours. After incubation, samples were stored at 4°C. Sequencing was performed within 72 hours of binding using a final concentration of 0.3 nmol/L. Each sample was sequenced using the DNA Sequencing Kit 2.0 (Pacific Biosciences). Sequencing data collection was performed on the PacBio RS (Pacific Biosciences) using C2/ C2 chemistry and movies of 55 minutes in each case. The SMRT Sequencing Analysis pipeline was implemented in Strawberry Perl and uses the NCBI BLAST software and the mEmboss NeedlemanWunsch pairwise alignment algorithm.
Isolation of Targeted Clonal Cell Populations
TALEN-transfected iPSCs were washed once with PBS and enzymatically dissociated with Accutase for 3 to 5 minutes at 37°C followed by gently pipetting to ensure single cell suspension. The cells were washed once in PBS and resuspended in E8 supplemented with Y-27632 (10 µmol/L). Double GFP + /RFP + cells were then sorted by fluorescence-activated cell sorter (FACSAria II; BD Biosciences), plated on 6-well plates at a clonal density of 1000 cells/well and allowed to recover. After 7 to 10 days, putative single cell-derived clones were manually picked, expanded, and maintained in standard conditions.
RNA Sequencing
Total RNA was isolated with the RNeasy Isolation kit with oncolumn DNase I treatment (Qiagen), and the quality of the RNA samples was assessed using the Agilent Bioanalyzer 2100 (Agilent). ERCC spike-in synthetic transcripts were added at manufacturer's recommended amounts (Life Technologies) and 1 µg of each RNA was enriched for poly-A RNA using the Dynabeads mRNA Direct Kit (Life Technologies) per manufacturer's protocol. Whole transcriptome library preparation was performed using 5 to 10 ng of fragmented enriched poly-A RNA according to the manufacturer's protocol (Ion Total RNA-Seq Kit V2 protocol; Life Technologies), followed by purification with AMPure beads (Beckman-Coulter Genomics). The quality and quantity of the libraries were assessed using the Agilent Bioanalyzer High Sensitivity Chip (Agilent). 
Allelic Discrimination by Digital PCR
Total RNA was extracted from iPSC-CMs at day 30 postdifferentiation using RNeasy Mini Kit (Qiagen), and complementary DNA (cDNA) preparation was carried out using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories). The cDNA (1 ng) was mixed with primers, probes, and ddPCR Supermix (total volume 20 μL). The final concentrations of the primers and the probe were 900 and 500 nmol/L, respectively. The following primers and probes were used for discriminating the expression of the R173W and the wild-type (WT) TNNT2 alleles; Fw: GAGGAGGAGAACAGGAG and Rv: GCATCATGTTGGACAAAGCC. wt-probe: [FAM] AGGATGAGGCCCGGAAGAAGA [BHQ] and mt-probe [HEX] AGGATGAGGCCTGGAAGAAGA [BHQ] . Droplet formation was carried out using a QX100 droplet generator. A rubber gasket was placed over the cartridge and loaded into the droplet generator. The emulsion (35 μL in volume) was then slowly transferred using a multichannel pipette to a 96-Well PCR Plates (Eppendorf). The plate was heat-sealed with foil, and the emulsion was cycled to end point per the manufacturer's protocol with an annealing temperature of 61°C. Finally, the samples were analyzed using a BioRad QX100 reader. The expression of TNNT2 was quantified by Real-Time qPCR (Applied Biosystems) using a custom TaqMan probe designed to detect the WT transcript after TALEN-mediated knockout (Fw: AGACGCCTCCAGGATCTGT, Rv: GCTTCTTCCTGCTCCTCCTC, Probe:
TALEN Off-Target Detection
Genomic DNA was extracted from genome-edited iPSC clones using the DNeasy Blood & Tissue Kit (Qiagen). The potential TALEN off-target sites were predicted in silico based on sequence homology using the bioinformatics tool PROGNOS. 15 The primers designed by PROGNOS were used to amplify the genomic regions of putative off-target sites by PCR. The PCR products were analyzed by Sanger sequencing.
ChIP-Seq Analysis
The raw Fastq files of ChIP-seq were aligned to human genome (hg19) by TMAP (https://github.com/iontorrent/TS/tree/master/ Analysis/TMAP), and then all duplicate reads aligned to same loci were removed. 16 Peak calling was applied by HOMER, 17 and the parameters are the following: style "factor", genome "hg19", foldchange cutoff 4.0 of DNA input, fold-change cutoff of peak calling 2.0, and P value cutoff 0.0001. Peaks were annotated by HOMER, and the nearest genes were assigned as the genes of the peaks. All sequences around coding promoters (upstream 400 bp, downstream 100 bp) were extracted, and motif enrichment analysis was performed using HOMER. Then KEGG enrichment analysis was performed using the GeneAnswers package (http://www.bioconductor.org/packages/release/bioc/html/GeneAnswers. html), and adjusted P value cutoff was 0.1. All alignment bam files were processed by IGVTools, and loaded to IGV genome browser 18 for the visualization of specific genes, all tracks normalized to 1 million reads.
Whole-Cell Patch Clamp Recordings
Contracting monolayer iPSC-CMs were enzymatically dispersed (Accutase, Sigma) and attached to Matrigel-coated glass coverslips (Warner) for whole-cell patch clamp recordings. These recordings were conducted using an EPC-10 patch clamp amplifier (HEKA, Lambrecht, Germany). About 3 to 4 mol/LΩ glass pipettes were prepared using thin-wall borosilicate glass (A-M System) with a micropipette puller (Sutter Instrument, P-97). 
Statistical Analysis
Unpaired 2-tailed Student t tests were used to determine the significance between 2 groups, assuming significance at P<0.05. The 1-way analysis of variance was used to determine whether there are any statistically significant differences among the means of three or more groups, with P<0.05 considered statistically significant. All values are expressed as the mean±SEM.
Results
Design, Construction, and Characterization of TALEN Constructs
We selected 88 genes associated with cardiomyopathies and CHDs ( Figure 1A ; Online Table I ), including genes implicated in syndromes for which clinical diagnosis may be challenging, such as CHARGE syndrome (chromodomain helicase DNAbinding protein 7 [CHD7] mutation), Leigh syndrome (SURF1 mutations), Holt-Oram syndrome (HOS; TBX5 mutations), Noonan syndrome, LEOPARD syndrome, Raf-1 proto-oncogene, serine/threonine kinase (RAF1) and protein tyrosine phosphatase, and nonreceptor type 11 (PTPN11) mutations. To knockout these genes in the human genome, we designed TALENs that target sequences located around the start codon, ATG, of each gene ( Figure 1B) . We constructed 1 TALEN pair construct for each gene using a library of preassembled tetramers/trimers through a 5-piece subcloning ligation. 12 The details of the TALEN design for each gene and the respective target site are shown in Online Table I . To validate the genome editing activities of the TALEN library in human iPSCs, we quantified the level of NHEJ using the SMRT technology.
14 Every TALEN pair tested was active and efficiently induced small deletions, insertions, or both at the target sites (Online Table II ). The individual TALEN pairs induced mutations with a frequency ranging from 0.5% to 50% (Figure 1C) , and the majority of the TALEN-mediated NHEJ outcomes were deletions of variable lengths within the spacer region, while insertion mutations were only observed in a few instances (Online Table II After TALEN transfection and FACS sorting, we screened single cell-derived clones for NHEJ events. We observed that the targeted loci were disrupted at high efficiency, with indels occurring in 33% to 100% of the clones screened (Table) . These results indicate that all of our TALEN constructs are highly active and can be used for gene knockout experiments.
Targeted Disruption of the Cardiac Troponin-T Gene Causes Sarcomere Disassembly
Mutations associated with cardiomyopathies are commonly inherited in an autosomal-dominant manner. Mutant proteins are thought to act through a dominant-negative mode that either interfere with normal function or assume a new function. In some instances, the mutant allele is inactivated, resulting in haploinsufficiency, whereby a single functional copy of the gene is insufficient to maintain the normal phenotype. Although mutations in the cardiac troponin T (TNNT2) gene are commonly implicated in familial hypertrophic cardiomyopathy, distinct mutations can also lead to DCM. 19 To address whether haploinsufficiency of TNNT2 is responsible for hypertrophic cardiomyopathy or DCM, we ablated either one or both TNNT2 alleles in human iPSCs by TALEN-mediated gene knockout in a single round of TALEN targeting. We generated both monoallelic (heterozygous) knockout (TNNT2 +/− ) and biallelic (homozygous) knockout (TNNT2 −/− ) iPSC lines (Figure 2A ). These TNNT2-knockout iPSC lines retained their pluripotency as assessed by immunostainining and gene expression assays of pluripotency markers (Online Figure I) . Upon differentiation, the cardiac troponin-T protein (cTnT) was not detected in TNNT2 −/− iPSC-CMs, whereas comparable levels of cTnT were observed in WT and TNNT2 +/− iPSC-CMs ( Figure 2B) . At the mRNA level, TNNT2 +/− iPSC-CMs had reduced expression of the nontargeted transcript compared with the parental iPSC-CMs ( Figure 2C ), suggesting that the cTnT protein levels are not regulated at the transcription level. Most likely a post-transcriptional mechanism, such as an increase in ribosome translational kinetics or lower protein turnover rates, is responsible for the comparable levels of cTnT protein expression in the TNNT2 +/− and WT iPSC-CMs. At the functional level, we observed that TNNT2 −/− iPSC-CMs displayed severe sarcomeric disarray ( Figure 2D ) and exhibited impaired intracellular Ca 2+ cycling (Online Figure II) . In contrast, TNNT2 +/− iPSC-CMs showed no functional or structural abnormalities, suggesting that one TNNT2 allele is sufficient to maintain normal cTnT protein expression and CM structure and function (Figure 2 ; Online Figure II) . These results suggest that haploinsufficiency is unlikely to explain the pathogenesis of familial cardiomyopathies associated with TNNT2 mutations.
Phenotypic Rescue of DCM by Targeted AllelicSpecific Knockout In Vitro
To test this hypothesis, we next disrupted the starting codon of TNNT2 gene in a patient-specific iPSC line harboring a missense mutation in exon 12 of the TNNT2 gene (NM_001001430.2: c.517 C>T; p.R173W) ( Figure 3A) . 20 We screened the TALEN-targeted clones for NHEJ events and identified an iPSC clone with a disruption of the starting codon of the mutant TNNT2 p.R173W allele (hereafter referred to as DCM-knockout) and without any detectable off-target mutations ( Figure 3A ; Online Table III ). This isogenic knockout line retained pluripotency as assessed by both immunostaining and gene expression assays of pluripotency markers (Online Figure III) . We differentiated the isogenic iPSC lines to iPSC-CMs and observed that the DCM-knockout iPSC-CMs had undetectable (<10%) mRNA expression of the mutant TNNT2 allele when compared with the parental line, consistent with the activation of the nonsense-mediated mRNA decay mechanism after the NHEJ repair process (Online Figure IV) . 21 In addition, we observed that the loss of the mutant allele ameliorated the DCM phenotype in vitro, including reversal of the sarcomere disarray ( Figure 3B and 3C) and improvement in Ca 2+ cycling parameters ( Figure 3D and 3E) . Taken together, these data suggest that the TNNT2 p.R173W is a dominant-negative mutation, and allelic-specific knockout could ameliorate the DCM phenotype in vitro.
Modeling HOS In Vitro
Cardiac development is a critical and complex embryological process requiring the integration of cell commitment, growth, looping, septation, and chamber specification. 22 Multiple transcription factors, including NKX2.5, GATA4, and TBX5, play important roles in cardiac development, and genetic studies have implicated dominant mutations in these genes in human CHD. TBX5 is a T-box-containing transcription factor, which like other T-box family members has been implicated in vertebrate tissue patterning and differentiation. [23] [24] [25] TBX5 represents one of the few genes that, when mutated, is known to cause CHD. 23 TBX5 haploinsufficiency is associated with HOS, a congenital disorder characterized by structural cardiac and limb abnormalities.
26 Tbx5 heterozygous null (Tbx5 +/− ) mice recapitulated the CHD seen in patients with HOS, whereas homozygous null mice (Tbx5 −/− ) ) knockout iPSCcardiac myocytes (CMs). Representative blots of the protein expression and densitometric analysis of TNNT2 protein expression levels normalized to α-sarcomeric actinin (ACTN2) in isogenic iPSC-CMs as indicated. Data represent mean±SEM of three independent differentiation experiments, *P<0.05. C, mRNA expression of the WT allele in the TNNT2 +/− and WT iPSC lines. A qPCR probe was designed to distinguish between the nonedited (WT) and the TALEN-mutated mRNA of the TNNT2 +/− iPSC-CMs. Gene expression levels were normalized to cardiac-specific gene ACTN2. Data represent mean±SEM of 3 independent differentiation experiments, *P<0.05. D, Representative immunofluorescence images of iPSC-CMs stained for the CM-specific markers cTnT (TNNT2, red) and α-sarcomeric actinin (ACTN2, green). DNA was counterstained with DAPI (blue). Scale bar, 20 μm. All the assays were performed at 30 days post differentiation with 1 isogenic pair. are growth arrested at E9.0 and die in utero by E10.5 due to severe heart defects. 26 Although the expression of many genes such as NPPA, GJA5, IRX4, MYL2, GATA4, NKX2.5, and HEY2 was reduced in TBX5-null hearts, 26 little is known about their downstream targets, and hence the molecular basis of HOS is poorly understood.
As a proof-of-principle experiment for creating CHD models, we generated a human cell-based HOS in vitro model by using TALEN-mediated NHEJ to knockout the TBX5 gene in iPSCs. In humans, TBX5 is highly regulated through alternative splicing, and several transcript variants encoding different isoforms have been described for TBX5. On the basis of RNAseq data of iPSC-CMs, the transcript variant 4 (NM_181486) is the predominant TBX5 isoform that is expressed in iPSCCMs. Of note, the presence of this transcript was also reported in the initial identification of TBX5 as the HOS gene. 27 The isoforms 1 (NM_000192) and 3 (NM_080717) were also detected in iPSC-CMs, albeit at low levels (Online Figure V) . Hence, we designed a TALEN pair and targeted the starting codon at exon 1 of the major isoform 4 and isoform 1 ( Figure  4A ). We identified an iPSC clone carrying a homozygous deletion, which resulted in frameshift mutations and an early termination of the TBX5 gene (hereafter referred to as TBX5-knockout; Figure 4B ). The isogenic TBX5-knockout iPSCs retained their pluripotency as assessed by immunostaining and gene expression assays of pluripotency markers (Online Figure VI) . We assessed potential off-target cutting sites in the edited clones using in silico prediction algorithms and did not detect any mutations in the 25 most likely off-target sites, suggesting a high specificity of the TBX5 TALEN pair (Online Table IV ). We then differentiated the isogenic iPSC clones into iPSC-CMs and confirmed that the TBX5 (isoforms 1 and 4) was not expressed at the protein level ( Figure 4C ). The directed differentiation protocol yielded cultures enriched (70%-85%) in cTnT+ iPSC-CMs in both WT and TBX5-knockout iPSC lines at day 15 post differentiation (Online Figure VII) that displayed a typical sarcomeric morphology ( Figure 4B ). As HOS is associated with electrophysiological abnormalities, 26, 28 we next characterized the action potential of the isogenic iPSC-CMs. Both TBX5-knockout and WT iPSCCMs displayed typical action potential morphologies, including ventricular-, atrial-, and nodal-like subtypes ( Figure 4D ; Online Table V) . However, we observed that 35% of TBX5-knockout iPSC-CMs exhibited marked proarrhythmic activity characterized by the development of depolarizing humps during phase 2 and 3 of the action potential that resemble early after depolarizations when compared with the parental iPSCCMs ( Figure 4E ).
Identification of Novel TBX5 Target Genes
To identify downstream targets and TBX5-dependent molecular networks, we next performed chromatin immunoprecipitation coupled to massively parallel sequencing (ChIP-seq) and RNA-seq analyses. The RNA-seq analysis of isogenic iPSC-CMs revealed profound changes in global gene expression. We identified 349 upregulated and 645 downregulated gene transcripts in TBX5-knockout when compared with the parental WT iPSC-CMs at a false discovery rate of 5%. Analysis of a representative subset of these genes by quantitative real-time-PCR in independent experiments validated our findings (Online Figure VIII) . Of note, the most significant downregulated gene was NPPA ( Figure 5A and 5B), a known direct target of TBX5. 29 As available antibodies for TBX5 are not suitable for genome-wide ChIP-seq, we used a lentivirus to express a FLAG-tagged TBX5 in WT iPSC-CMs. We performed FLAG-mediated ChIP-seq to define the binding sites of TBX5 genome wide. We identified 4518 TBX5-bound peaks that were significantly enriched in the TBX5-FLAG sample compared with the control sample (false discovery rate <0.01). To validate the ChIP-seq peaks, we next performed de novo motif analysis to investigate the predominant motifs enriched in TBX5-binding sites. As expected, the identified peaks were highly enriched for the previously experimentally discovered motif of TBX5 (Online Figure XI) . 29 Next, to define the direct TBX5 gene regulatory networks, we correlated TBX5-binding and TBX5-mediated gene regulation by combining the gene set containing TBX5 peaks with the genes differentially expressed between the TBX5-knockout and WT iPSC-CMs. We annotated the TBX5-bound regions to the nearest transcription-starting site and identified 341 candidate TBX5 direct target genes (118 up and 223 downregulated genes; Figure 5C ). To further refine the TBX5 target genes, we analyzed the 223 downregulated gene set and revealed important genes associated with CM function, such as cardiac myosin-binding protein C (MYBPC3), titin (TTN), calsequestrin (CASQ2), natriuretic peptide type A (NPPA), connexin 43 (GJA5), and sodium voltage-gated channel α subunit 5 (SCN5A). Remarkably, we found that 40% of the TBX5 candidate target genes were enriched in unexpected pathways ostensibly unrelated to processes associated with heart function. These pathways included extracellular matrix (ECM)-receptor interaction, focal adhesion, and protein digestion and absorption ( Figure 5D ). We found that the TBX5 was bound to promoter regions of key components of the embryonic provisional matrix, including perlecan (HSPG2), 30 fibronectin (FN1), 31, 32 fibulin-1 (FBLN1), 33 collagen XIV (COL14A3), 34 versican (VCAN), [35] [36] [37] and versican-degrading protease ADMTS9. 34 These ECM components play essential roles in cardiac development and are indispensable for normal heart development by regulating heart tube segmentation, chamber specification, endocardial cushion formation, interventricular septal formation, and CM differentiation. 38 Taken together, these data suggest that genes encoding embryonic ECM components are direct TBX5 targets and represent potential novel candidate genes associated with HOS and CHD.
Discussion
In the past decade, advances in cardiovascular genetics have uncovered a plethora of genes associated with inherited cardiomyopathies. Delineating the role of cardiomyopathy-associated genes and variants could provide a better understanding to the underlying pathogenic mechanisms and provide potential targets for therapeutic interventions. The advent of new technologies, such as iPSC and genome editing with designer nucleases, has provided an unprecedented opportunity for disease modeling in vitro. As the development of a highly active TALEN architecture 39 and simplified engineering platforms, 12 TALEN-mediated genome editing has been demonstrated in diverse cell types, including pluripotent stem cells. 12, [40] [41] [42] The relatively unconstrained target site requirements 43 and the high degree of specificity of TALENs provide a valuable tool for genome editing.
In principle, a TALEN pair can be targeted to any site in the genome, allowing more freedom and flexibility in target site selection with minimal off-target mutagenesis when compared with newer technologies, such as CRISPR/Cas9. [44] [45] [46] In this study, we designed, constructed, and validated TALEN vectors as an effective tool for gene knockout in human iPSCs. The cardiomyopathy TALEN-based panel consists of 88 TALEN pairs that are designed to knockout genes that are associated with cardiomyopathies and CHD. Every TALEN pair was individually validated in human iPSCs and found to be active at the targeted locus. Furthermore, we have established that the target sites needs to be carefully chosen as TALEN pairs that target either the start codon (ATG) or regions immediately after are more effective in disrupting the open reading frame of the targeted gene. In contrast, indels at the 5-end UTR are inefficient in modifying the open reading frame. It should also be noted that although the start codon is deleted, there might be a downstream translation starting sites that could function alternatively.
An important issue in cardiovascular genetics is determining whether putative mutations are causative of the disease, and establishing causality for putative disease causing variants is becoming increasingly clinically relevant. As a proofof-concept, we showed that the DCM phenotype in iPSC-CMs was ameliorated by selectively disrupting the starting codon of a DCM-causing TNNT2 allele in a patient-specific iPSCs. In addition, using a similar strategy, we created a CHD model of HOS in vitro and identified several novel genes that are associated with TBX5 haploinsufficiency, providing an entry point to understand the complex phenotypes caused by TBX5 haploinsufficiency and the pathogenesis of HOS. Taken together, these results demonstrated that TALEN-mediated gene knockout strategies in iPSCs could be used to interrogate disease-causing mutations in a wide range of diseases and cell types as well as to model complex diseases in vitro.
In summary, combining iPSC and genome editing technologies holds great promise for advancing fundamental knowledge of the pathogenesis of inherited cardiomyopathies and CHD. The methods, strategies, and constructs developed in this study provide a validated, readily available resource for cardiovascular research that simplifies the custom generation of iPSC knockout cell lines and will, therefore, have a broad applicability for the generation of iPSC-based disease models and functional studies.
